NeoGenomics, Inc. Aktie News

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will share at ESMO 2025 how its RaDaR ST MRD assay can support pharmaceutical partners across oncology research and clinical trials.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, Oct. 28, 2025.

FORT MYERS, Fla.--(BUSINESS WIRE)--Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera.

Neo Performance Materials Inc. (OTCPK:NOPMF) Q2 2025 Earnings Conference August 12, 2025 10:00 AM ET Company Participants Irina Kuznetsova - Corporate Participant Jonathan Baksh - Executive VP & CFO Rahim Suleman - CEO, President & Director Conference Call Participants Ian Brooks Gillies - Stifel Nicolaus Canada Inc., Research Division J. Marvin Wolff - Paradigm Capital Inc., Research Division ...

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company's PanTracer portfolio.

NeoGenomics, Inc. (NASDAQ:NEO ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Anthony P. Zook - CEO & Director Jeffrey S.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2025.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025.